Overview
Wegovy and Ozempic both contain the same active ingredient -- semaglutide -- manufactured by the same company, Novo Nordisk. Despite this, they are priced differently, covered differently by insurance, and occupy distinct places in the prescription drug market. Understanding why can help patients and prescribers navigate the cost landscape more effectively.
This page explains the pricing differences between these two medications, the insurance dynamics that drive out-of-pocket costs, and available options for reducing expenses.
Why the Same Drug Has Different Prices
Although both medications contain semaglutide, they are approved for different indications, come in different dose strengths, and are marketed as separate products.
Ozempic is FDA-approved for the treatment of type 2 diabetes. Its maximum approved dose is 2 mg per week, and its list price is approximately $935 to $1,050 per month depending on the dose.
Wegovy is FDA-approved for chronic weight management. It is available at higher doses (up to 2.4 mg per week) and carries a list price of approximately $1,349 to $1,650 per month.
The higher price for Wegovy reflects, in part, the higher maximum dose and its positioning as a weight-management medication. Manufacturers typically price products based on multiple factors including clinical trial investment, market positioning, and expected payer coverage dynamics.
Insurance Landscape
The most impactful cost difference between Wegovy and Ozempic for many patients is not the list price but the insurance coverage.
Ozempic benefits from substantially broader insurance coverage because it is indicated for type 2 diabetes, a condition that virtually all health plans cover. Most commercial insurance plans, Medicare Part D plans, and Medicaid programs include diabetes medications on their formularies, though Ozempic's specific tier placement and copay levels vary by plan.
Wegovy faces a more challenging coverage landscape. Because it is indicated for weight management, it falls into a category that many plans have historically excluded. While coverage for anti-obesity medications has been expanding, a significant number of employer-sponsored plans and government programs still do not cover weight-loss drugs, or cover them only with substantial restrictions.
This coverage gap means that a patient with type 2 diabetes prescribed Ozempic may pay a modest copay, while a patient with obesity prescribed Wegovy for weight management may face the full list price. The clinical and financial situations can be quite different even though the underlying molecule is the same.
Savings Cards and Patient Assistance
Both products have manufacturer savings programs, though they function within different coverage environments.
Ozempic savings card: Novo Nordisk offers a savings card that may reduce copays for commercially insured patients. Because most insured patients already have coverage for Ozempic, this card typically reduces an existing copay.
Wegovy savings card: A savings card is also available for Wegovy. For patients whose insurance covers Wegovy, the card can reduce copays significantly. For patients without coverage, however, the savings card alone may not offset the full list price.
Neither savings card is available to patients with government-funded insurance (Medicare, Medicaid, TRICARE). Novo Nordisk also operates patient assistance programs for qualifying uninsured or underinsured patients who meet income requirements.
Off-Label Considerations
Some patients seek an Ozempic prescription for weight loss rather than Wegovy, drawn by better insurance coverage and a lower list price. While providers may legally prescribe off-label, plans may deny coverage if the indication does not match the drug's approved use. Additionally, the maximum Ozempic dose (2 mg) is lower than the Wegovy maintenance dose (2.4 mg) studied in the pivotal weight-loss trials.
Patients should discuss any off-label use openly with their healthcare provider and understand both the insurance and clinical implications.
Key Takeaways
The cost difference between Wegovy and Ozempic is driven less by the medication itself and more by the insurance and regulatory framework surrounding each product's approved indication. Patients considering semaglutide for either diabetes or weight management should work with their healthcare provider and pharmacist to understand their specific coverage situation and explore all available savings options before starting treatment.
Prices, coverage policies, and savings programs are subject to change. The information on this page reflects conditions as of early 2026 and should be verified with current sources before making treatment decisions.
Related Pages
This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.